Takeda To Develop Cancer Drugs As It Makes Up For Patent Losses
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical plans to overcome expiration of some of its major drug patents beginning next year by concentrating on cancer drugs and licensing products from other makers